Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07148791
Recruiting Phase 2

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

NCT07148791 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Phase 2
Started
2025-09-05
Last updated
2025-09-03

Condition(s) studied

IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Investigational drug(s) / intervention(s)

Anti-BCMA-CD19 CAR-T cells

Anti-BCMA-CD19 CAR-T cells: Anti-BCMA-CD19 CAR-T cell injection is an autologous, dual-target chimeric antigen receptor T-cell therapy designed to target CD19 and BCMA antigens. Peripheral blood mononuclear cells (PBMCs) are collected from each participant and modified ex vivo using lentiviral transduction to express the CAR construct. Lymphodepletion with cyclophosphamide (250 mg/m\^2/day, IV) and fludarabine (30 mg/m\^2/day, IV) is administered for 3 days (Day -5 to Day -3). The doses of fludarabine and cyclophosphamide may be adjusted based on the patient's clinical condition. CAR-T cells are infused intravenously on Day 0 at one of three dose levels (1x10\^6, 2x10\^6, or 3x10\^6 CAR+ T cells/kg, ±20%). This product is being investigated in patients with relapsed or refractory IgG4-related disease (IgG4-RD) to assess safety and preliminary efficacy.

Study summary

The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not improved after standard treatments such as glucocorticoids or rituximab.

The main questions this study aims to answer are:

* What medical problems (side effects) occur after receiving anti-BCMA-CD19 CAR-T cell therapy?
* Does anti-BCMA-CD19 CAR-T cell therapy improve IgG4-RD disease activity scores at 12 weeks and 26 weeks?

Participants will:

* Have their own blood immune cells collected by a procedure called leukapheresis
* Receive short-term chemotherapy to prepare the immune system
* Receive one intravenous infusion of anti-BCMA-CD19 CAR-T cells
* Return for regular clinic visits over 26 weeks for safety checks, blood tests, and imaging
* May be followed for up to one year in total

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: To participate, subjects must meet all of the following criteria: 1. Aged 18 to 75 years, inclusive, regardless of sex. 2. Meet the 2019 ACR/EULAR classification criteria for IgG4-related disease. 3. Involvement of two or more important systems/sites (including but not limited to the pancreas, bile ducts, kidneys and dura mater). 4. Relapsed or refractory IgG4-RD: The disease either remains active after 3 months of glucocorticoid and/or rituximab therapy or relapses within 6 months post-treatment. 5. Important organ function meeting the following conditions: * Bone marrow: (i) neutrophil count ≥1×10\^9/L (excluding disease-related neutropenia); (ii) hemoglobin ≥60 g/L. * Hepatic function: ALT≤3×ULN (elevation caused by disease may be excluded); AST≤3×ULN (elevation caused by disease may be excluded); TBIL≤1.5×ULN (elevation caused by disease may be excluded). * Renal function: creatinine clearance (Cockcroft-Gault formula) ≥30 ml/min (excluding acute decline due to disease). * Coagulation: international normalized ratio (INR) ≤ 1.5×ULN, prothrombin time (PT) ≤ 1.5×ULN * Cardiac function: stable hemodynamics. 6. Women of childbearing potential and male subjects with partners of childbearing potential must use medically accepted contraception or abstain during study treatment and for at least 12 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must not be breastfeeding. 7. Voluntary participation in this clinical study with signed informed consent and willingness to comply with study procedures and follow-up. 8. Patent superficial peripheral veins adequate for intravenous infusion. Exclusion Criteria: Subjects will be excluded if any of the following criteria are met: 1. History of severe drug allergy or allergic constitution. 2. Current or suspected uncontrollable or treatment-requiring fungal, bacterial, viral or other infections. 3. Central nervous system disease (excluding disease-related epilepsy, psychosis, organic brain syndrome, cerebrovascular accident, encephalitis or central nervous system vasculitis). 4. Cardiac insufficiency that precludes participation. 5. Congenital immunoglobulin deficiency. 6. Congenital malformation or nutritional disorder causing severe organ impairment. 7. History of malignancy within the past five years. 8. End-stage renal failure. 9. Positive hepatitis B surface antigen and hepatitis B core antibody with HBV-DNA titers above the assay limit of detection; positive hepatitis C antibody with HCV-RNA positivity; positive human immunodeficiency virus antibody; positive syphilis serology. 10. Psychiatric disorders or severe cognitive impairment. 11. Participation in other clinical trials within three months before enrollment. 12. Receipt of any investigational drug within 12 weeks before screening or within five half-lives of the agent (whichever is longer). 13. Pregnant or intending to become pregnant. 14. Any other reason deemed by the investigator to preclude enrollment.

Primary outcome measure(s)

  • Safety - Incidence of Dose-Limiting Toxicity (DLT) and Adverse Events Related to CAR-T Cells — Baseline to Week 26
    Any grade ≥3 toxicity related to CAR-T cells within 28 days post-infusion is considered a DLT, except: * Grade 3 CRS resolving to ≤ grade 2 within 3 days; * Grade 3/4 TLS \<7 days; * Hematologic: grade 3 neutropenia/anemia/thrombocytopenia at any time or grade 4 \<14 days (\<21 days for thrombocytopenia); other cytopenias excluded; * Non-hematologic: fever (incl. febrile neutropenia), grade 3 diarrhea \<7 days, grade 3 nausea/vomiting \<7 days, grade 3 fatigue \<7 days; * Grade 3/4 elevations in liver enzymes, bilirubin, creatinine, or BUN \<7 days; * Asymptomatic lipase elevation without pancreatitis; * Asymptomatic grade 3 non-hematologic lab abnormality reversible \<7 days (to baseline or ≤ grade 2). Safety monitoring includes AEs, SAEs, AESIs, CRS, and ICANS, with grading and frequency recorded.
  • Efficacy - Changes in IgG4-RD RI — Baseline, Week 12 and Week 26
    IgG4-RD Responder Index is a validated score used to assess disease activity

Trial sites (1)

FacilityCityRegionStatus
Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital Beijing Beijing Municipality Recruiting

More Chinese PLA General Hospital trials in China

Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study Starting soon
Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy Starting soon
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma Recruiting
Orthopedic Intelligent Navigation System in the Treatment of Fresh Femoral Neck Fractures Starting soon
Thulium Laser Enucleation With Bladder Neck Incision for Small-Volume Benign Prostatic Hyperplasia Starting soon

Other trials for the same condition

Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement Starting soon
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease Recruiting
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease Starting soon
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease Recruiting
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07148791 on ClinicalTrials.gov ↗ ← All trials in China